Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
Werner Wenning(Ortenau Klinikum), Ralf Gold(St. Josef-Hospital), Aiden Haghikia(Friedrich-Alexander-Universität Erlangen-Nürnberg), David B. Clifford(Washington University in St. Louis), Jörg Laubenberger(University Medical Center Freiburg), Peter F. Behrens(Ortenau Klinikum), Andrew Chan(Infosys (India))
Cited by 178
Related Papers
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
|Brain|2011|1.2k
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine
|Immunity|2015|919
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
|New England Journal of Medicine|2006|792
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706